Zacks Research Has Pessimistic Outlook of MMSI Q1 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Stock analysts at Zacks Research reduced their Q1 2025 earnings estimates for Merit Medical Systems in a research note issued on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will earn $0.76 per share for the quarter, down from their previous estimate of $0.81. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q2 2025 earnings at $0.96 EPS, Q4 2025 earnings at $1.02 EPS, Q1 2026 earnings at $0.74 EPS, Q2 2026 earnings at $1.08 EPS, Q3 2026 earnings at $1.10 EPS, Q4 2026 earnings at $1.15 EPS and FY2027 earnings at $4.34 EPS.

MMSI has been the topic of a number of other reports. Wells Fargo & Company reduced their price objective on shares of Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Piper Sandler reissued an “overweight” rating and set a $116.00 price objective (up previously from $114.00) on shares of Merit Medical Systems in a report on Wednesday, January 29th. Raymond James boosted their price target on Merit Medical Systems from $105.00 to $110.00 and gave the stock an “outperform” rating in a report on Tuesday, December 31st. Needham & Company LLC decreased their price objective on Merit Medical Systems from $122.00 to $116.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Finally, Canaccord Genuity Group decreased their price target on Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Merit Medical Systems currently has an average rating of “Moderate Buy” and a consensus target price of $110.78.

Merit Medical Systems Stock Performance

Shares of NASDAQ:MMSI opened at $101.28 on Thursday. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57. Merit Medical Systems has a 12-month low of $70.70 and a 12-month high of $111.45. The company’s 50 day moving average price is $103.82 and its two-hundred day moving average price is $100.71. The firm has a market cap of $5.96 billion, a PE ratio of 49.65, a PEG ratio of 2.34 and a beta of 0.91.

Hedge Funds Weigh In On Merit Medical Systems

Several institutional investors and hedge funds have recently made changes to their positions in MMSI. Peak Retirement Planning Inc. bought a new stake in Merit Medical Systems in the 4th quarter worth $875,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Merit Medical Systems by 17.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 165,344 shares of the medical instruments supplier’s stock worth $15,992,000 after buying an additional 24,528 shares during the period. iSAM Funds UK Ltd bought a new position in shares of Merit Medical Systems in the 4th quarter worth about $424,000. Virtus Investment Advisers Inc. lifted its position in Merit Medical Systems by 45.7% during the 4th quarter. Virtus Investment Advisers Inc. now owns 11,192 shares of the medical instruments supplier’s stock valued at $1,082,000 after acquiring an additional 3,513 shares during the period. Finally, Tidal Investments LLC boosted its stake in Merit Medical Systems by 3,197.9% during the fourth quarter. Tidal Investments LLC now owns 342,912 shares of the medical instruments supplier’s stock worth $33,166,000 after acquiring an additional 332,514 shares in the last quarter. Institutional investors own 99.66% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Raul Jr. Parra sold 12,451 shares of the stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $98.81, for a total transaction of $1,230,283.31. Following the sale, the chief financial officer now owns 24,201 shares of the company’s stock, valued at approximately $2,391,300.81. This represents a 33.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Brian G. Lloyd sold 25,000 shares of the stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $99.50, for a total transaction of $2,487,500.00. Following the completion of the sale, the insider now owns 38,993 shares in the company, valued at $3,879,803.50. This represents a 39.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 109,132 shares of company stock worth $11,139,521 over the last quarter. 3.70% of the stock is currently owned by company insiders.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.